Toll Free: 1-888-928-9744

MGB Biopharma Limited - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 25 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

MGB Biopharma Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'MGB Biopharma Limited - Product Pipeline Review - 2015', provides an overview of the MGB Biopharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MGB Biopharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of MGB Biopharma Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of MGB Biopharma Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the MGB Biopharma Limited's pipeline products

Reasons to Buy

- Evaluate MGB Biopharma Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of MGB Biopharma Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the MGB Biopharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of MGB Biopharma Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of MGB Biopharma Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of MGB Biopharma Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 MGB Biopharma Limited Snapshot 4 MGB Biopharma Limited Overview 4 Key Information 4 Key Facts 4 MGB Biopharma Limited - Research and Development Overview 5 Key Therapeutic Areas 5 MGB Biopharma Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 MGB Biopharma Limited - Pipeline Products Glance 9 MGB Biopharma Limited - Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 MGB Biopharma Limited - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 MGB Biopharma Limited - Drug Profiles 12 MGBBP-3 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Small Molecule to Inhibit DNA Synthesis for Fungal Infections 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Small Molecule to Inhibit DNA Synthesis for Gram-Negative Bacterial Infections 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Small Molecule to Inhibit DNA Synthesis for Parasitic Diseases 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecule to Inhibit DNA Synthesis for Viral Infection 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 MGB Biopharma Limited - Pipeline Analysis 18 MGB Biopharma Limited - Pipeline Products by Target 18 MGB Biopharma Limited - Pipeline Products by Route of Administration 19 MGB Biopharma Limited - Pipeline Products by Molecule Type 20 MGB Biopharma Limited - Pipeline Products by Mechanism of Action 21 MGB Biopharma Limited - Recent Pipeline Updates 22 MGB Biopharma Limited - Locations And Subsidiaries 23 Head Office 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 24 Disclaimer 25
List of Tables
MGB Biopharma Limited, Key Information 4 MGB Biopharma Limited, Key Facts 4 MGB Biopharma Limited - Pipeline by Indication, 2015 6 MGB Biopharma Limited - Pipeline by Stage of Development, 2015 7 MGB Biopharma Limited - Monotherapy Products in Pipeline, 2015 8 MGB Biopharma Limited - Phase I, 2015 9 MGB Biopharma Limited - Preclinical, 2015 10 MGB Biopharma Limited - Discovery, 2015 11 MGB Biopharma Limited - Pipeline by Target, 2015 18 MGB Biopharma Limited - Pipeline by Route of Administration, 2015 19 MGB Biopharma Limited - Pipeline by Molecule Type, 2015 20 MGB Biopharma Limited - Pipeline Products by Mechanism of Action, 2015 21 MGB Biopharma Limited - Recent Pipeline Updates, 2015 22



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify